NOVEL LINEAR PEPTIDE UNIVERSAL MALARIA VACCINES

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 本研究提案的总体目标是优化疟疾模块嵌合疫苗（MCV）的设计、组成和配方，作为控制流行地区疾病的有效干预措施。第一个具体目标将侧重于制定策略，以构建和提供稳定有效的MCV，可以保护恒河猴免受猴疟疾寄生虫食蟹猴疟原虫的实验挑战。该项目的第二个目标将建立在设计具有保护人类免受间日疟原虫侵害潜力的MCV所获得的经验的基础上。由间日疟原虫引起的疟疾是一个主要的世界性健康问题，估计每年有8000万病例。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this research proposal is to optimize the design, composition and formulation of malaria Modular Chimeric Vaccines (MCVs) as effective intervention measures to control the disease in endemic areas. The first specific aim will focus on developing strategies to construct and deliver stable and efficacious MCVs that can protect rhesus macaques against the experimental challenge with a simian malaria parasite Plasmodium cynomolgi. The second aim of the project will build on the experience gained to design MCVs with the potential to protect humans against P. vivax. Malaria caused by P. vivax is a major worldwide health problem with an estimated 80 million cases annually.